OBJECTIVE: To identify behavioral, social, and structural factors associated with time from HIV seroconversion to antiretroviral therapy (ART) initiation among people who use injection drugs (PWID). DESIGN: Two complementary prospective cohorts of PWID linked to comprehensive ART dispensation records in a setting of universal no-cost HIV/AIDS treatment and care. METHODS: Multivariable extended Cox models of time to ART initiation among baseline HIV-seronegative PWID who seroconverted after recruitment adjusted with a time-updated measure of clinical eligibility for ART. RESULTS: We included 133 individuals of whom 98 (74%) initiated ART during follow-up at a rate of 12.4 per 100 person-years. In a multivariable model adjusted for ART eligibility, methadone maintenance therapy [adjusted hazard ratio (AHR) = 2.37, 95% confidence interval (95% CI): 1.56-3.60] and a more recent calendar year of observation (AHR = 1.06, 95% CI: 1.00-1.12) were associated with more rapid ART initiation, whereas informal income generation (AHR = 0.51, 95% CI: 0.32-0.79) and incarceration (AHR = 0.52, 95% CI: 0.28-0.97) were negatively associated with ART initiation. CONCLUSION: In this sample of community-recruited HIV-positive PWID with well defined dates of HIV seroconversion, we found that two measures related to the criminalization of illicit drug use each independently delayed ART initiation regardless of clinical eligibility. Engagement in methadone promoted ART initiation. Programs to scale-up HIV treatment among PWID should consider decreased criminalization of PWID and increased access to opioid substitution therapy to optimize the impact of ART on HIV/AIDS-associated morbidity, mortality, and HIV transmission.
OBJECTIVE: To identify behavioral, social, and structural factors associated with time from HIV seroconversion to antiretroviral therapy (ART) initiation among people who use injection drugs (PWID). DESIGN: Two complementary prospective cohorts of PWID linked to comprehensive ART dispensation records in a setting of universal no-cost HIV/AIDS treatment and care. METHODS: Multivariable extended Cox models of time to ART initiation among baseline HIV-seronegative PWID who seroconverted after recruitment adjusted with a time-updated measure of clinical eligibility for ART. RESULTS: We included 133 individuals of whom 98 (74%) initiated ART during follow-up at a rate of 12.4 per 100 person-years. In a multivariable model adjusted for ART eligibility, methadone maintenance therapy [adjusted hazard ratio (AHR) = 2.37, 95% confidence interval (95% CI): 1.56-3.60] and a more recent calendar year of observation (AHR = 1.06, 95% CI: 1.00-1.12) were associated with more rapid ART initiation, whereas informal income generation (AHR = 0.51, 95% CI: 0.32-0.79) and incarceration (AHR = 0.52, 95% CI: 0.28-0.97) were negatively associated with ART initiation. CONCLUSION: In this sample of community-recruited HIV-positive PWID with well defined dates of HIV seroconversion, we found that two measures related to the criminalization of illicit drug use each independently delayed ART initiation regardless of clinical eligibility. Engagement in methadone promoted ART initiation. Programs to scale-up HIV treatment among PWID should consider decreased criminalization of PWID and increased access to opioid substitution therapy to optimize the impact of ART on HIV/AIDS-associated morbidity, mortality, and HIV transmission.
Authors: Deborah Donnell; Jared M Baeten; James Kiarie; Katherine K Thomas; Wendy Stevens; Craig R Cohen; James McIntyre; Jairam R Lingappa; Connie Celum Journal: Lancet Date: 2010-05-26 Impact factor: 79.321
Authors: Sasha Uhlmann; M-J Milloy; Thomas Kerr; Ruth Zhang; Silvia Guillemi; David Marsh; Robert S Hogg; Julio S G Montaner; Evan Wood Journal: Addiction Date: 2010-03-10 Impact factor: 6.526
Authors: Julio S G Montaner; Robert Hogg; Evan Wood; Thomas Kerr; Mark Tyndall; Adrian R Levy; P Richard Harrigan Journal: Lancet Date: 2006-08-05 Impact factor: 79.321
Authors: Anita Palepu; Mark W Tyndall; Ruth Joy; Thomas Kerr; Evan Wood; Natasha Press; Robert S Hogg; Julio S G Montaner Journal: Drug Alcohol Depend Date: 2006-03-20 Impact factor: 4.492
Authors: H Irene Hall; Ruiguang Song; Philip Rhodes; Joseph Prejean; Qian An; Lisa M Lee; John Karon; Ron Brookmeyer; Edward H Kaplan; Matthew T McKenna; Robert S Janssen Journal: JAMA Date: 2008-08-06 Impact factor: 56.272
Authors: R Weber; M Huber; M Rickenbach; H Furrer; L Elzi; B Hirschel; M Cavassini; E Bernasconi; P Schmid; B Ledergerber Journal: HIV Med Date: 2009-05-26 Impact factor: 3.180
Authors: Kora DeBeck; Kate Shannon; Evan Wood; Kathy Li; Julio Montaner; Thomas Kerr Journal: Drug Alcohol Depend Date: 2007-06-11 Impact factor: 4.492
Authors: Kathryn E Lancaster; William C Miller; Tetiana Kiriazova; Riza Sarasvita; Quynh Bui; Tran Viet Ha; Kostyantyn Dumchev; Hepa Susami; Erica L Hamilton; Scott Rose; Rebecca B Hershow; Vivian F Go; David Metzger; Irving F Hoffman; Carl A Latkin Journal: AIDS Educ Prev Date: 2019-04
Authors: Ezequiel Blumenkrans; Jonah Hamilton; N A Mohd Salleh; Angela Kaida; Will Small; Rolando Barrios; M-J Milloy Journal: J Correct Health Care Date: 2022-06-27
Authors: Surita Parashar; Alexandra B Collins; Julio S G Montaner; Robert S Hogg; Michael-John Milloy Journal: Curr Opin HIV AIDS Date: 2016-09 Impact factor: 4.283
Authors: William C Miller; Irving F Hoffman; Brett S Hanscom; Tran V Ha; Kostyantyn Dumchev; Zubairi Djoerban; Scott M Rose; Carl A Latkin; David S Metzger; Kathryn E Lancaster; Vivian F Go; Sergii Dvoriak; Katie R Mollan; Sarah A Reifeis; Estelle M Piwowar-Manning; Paul Richardson; Michael G Hudgens; Erica L Hamilton; Jeremy Sugarman; Susan H Eshleman; Hepa Susami; Viet Anh Chu; Samsuridjal Djauzi; Tetiana Kiriazova; Duong D Bui; Steffanie A Strathdee; David N Burns Journal: Lancet Date: 2018-09-01 Impact factor: 202.731
Authors: Aida Roziana Ramlan; Nor Ilyani Mohamed Nazar; Afidalina Tumian; Norny Syafinaz Ab Rahman; Dzawani Mohamad; Mat Sharil Abdul Talib; Khairul Faizan M Zakaria; Muhammad Azzim Izuddin; Nadia Akmal Zainal Abidin; Syarifah Syafiqah T Syed Manso; Wan Nur Khairiyah Wan Hassan Journal: J Pharm Bioallied Sci Date: 2020-11-05